Roth Positive on BioLineRx (BLRX) Amid Latest BL-8040 Phase 2a Data in r/r AML

FREE Breaking News Alerts from StreetInsider.com!

E-mail Address

StreetInsider.com Top Tickers, 8/17/2026

1. SPY
2. EYPT
3. GNK
4. NVDA
5. AZN
6. SPCX
7. FNGR
8. PLUR
9. HIVE
10. GSAT

Go back to Roth Positive on BioLineRx (BLRX) Amid Latest BL-8040 Phase 2a Data in r/r AML

BioLineRx Presents Final Results from Phase 2a Trial for Relapsed/Refractory AML at SOHO Conference

September 8, 2016 7:00 AM EDT

TEL AVIV, Israel, September 8, 2016 /PRNewswire/ --

BioLineRx Ltd. (NASDAQ/TASE: BLRX) announced that the successful final results of BL-8040's Phase 2a clinical trial in relapsed or refractory acute myeloid leukemia (r/r AML) were presented yesterday evening at the 4th Annual Meeting of the Society of Hematologic Oncology (SOHO), being held September 7-10, 2016, in Houston, Texas.

BL-8040, BioLineRx's lead oncology platform, is a short cyclic peptide that functions as a high-affinity antagonist for CXCR4, a chemokine receptor that is directly involved in tumor progression, angiogenesis,... More

BioLineRx Announces Clinical Research Collaboration to Investigate Combination of BL-8040 with Atezolizumab in Multiple Oncology Indications

September 7, 2016 7:00 AM EDT

TEL AVIV, Israel, September 7, 2016 /PRNewswire/ --

BioLineRx Ltd. (NASDAQ/TASE: BLRX) today announced that it has entered into a collaboration with Genentech, a member of the Roche Group, to support several Phase 1b studies investigating BioLineRx's BL-8040 in combination with Atezolizumab, Genentech's anti-PDL1 cancer immunotherapy, in multiple cancer indications. The Phase 1b studies will evaluate the clinical response, safety and tolerability of the combination of these therapies, as well as multiple pharmacodynamic parameters, in hematologic malignancies and solid tumors.

Under the agreement, Genentech will sponsor and conduct several... More